Saitama, Japan

Hidekazu Kayano

This inventor holds 1 USPTO granted patent. Top assignee: Saitama Medical University. Active years: 2024.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Hidekazu Kayano

Introduction

Hidekazu Kayano is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of biomaterials through his innovative patent. His work focuses on enhancing the understanding of cell nucleus states in biomaterial samples.

Latest Patents

Hidekazu Kayano holds a patent for an "Estimator learning device, estimator learning method, and estimator learning program." This invention includes an image acquisition unit that captures stained images of biomaterial samples across multiple wavebands. It also features a cell nucleus extraction unit that identifies the cell nucleus region in each stained image. Additionally, a color information acquisition unit calculates absorbance in the cell nucleus region for each waveband. The estimator learning unit then trains an estimator to determine whether the cell nucleus is in a prescribed state based on the absorbance data.

Career Highlights

Kayano is affiliated with Saitama Medical University, where he applies his expertise in biomaterials and imaging technology. His work has implications for medical research and diagnostics, particularly in understanding cellular conditions.

Collaborations

One of his notable collaborators is Masahiro Ishikawa, with whom he has worked on various projects related to his patent.

Conclusion

Hidekazu Kayano's innovative contributions to the field of biomaterials and imaging technology highlight the importance of research in understanding cellular states. His patent reflects a significant advancement in the estimation of cell nucleus conditions, which can have far-reaching implications in medical diagnostics.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…